CompletedNCT06060197

MCT8 Deficiency Caregiver Study

Studying Allan-Herndon-Dudley syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Rare Thyroid Therapeutics International AB
Principal Investigator
Mark Larkin, PhD
Vitaccess Limited
Enrollment
21 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2024

Study locations (1)

Collaborators

Vitaccess Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06060197 on ClinicalTrials.gov

Other trials for Allan-Herndon-Dudley syndrome

Additional recruiting or active studies for the same condition.

See all trials for Allan-Herndon-Dudley syndrome →

← Back to all trials